5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.77▼ | 1.80▼ | 1.80▼ | 1.72▲ | 1.46▲ |
MA10 | 1.79▼ | 1.81▼ | 1.81▼ | 1.64▲ | 1.23▲ |
MA20 | 1.80▼ | 1.80▼ | 1.74▲ | 1.48▲ | 0.93▲ |
MA50 | 1.76▲ | 1.71▲ | 1.65▲ | 1.22▲ | 0.75▲ |
MA100 | 1.70▲ | 1.65▲ | 1.51▲ | 0.93▲ | 1.03▲ |
MA200 | 1.64▲ | 1.48▲ | 1.37▲ | 0.76▲ | 8.42▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.009▼ | -0.011▼ | -0.003▼ | 0.022▲ | 0.094▲ |
RSI | 42.227▼ | 50.855▲ | 57.623▲ | 63.837▲ | 72.747▲ |
STOCH | 0.000▼ | 47.661 | 62.856 | 73.676 | 69.845 |
WILL %R | -100.000▼ | -73.684 | -36.364 | -12.121▲ | -6.452▲ |
CCI | -101.785▼ | -157.506▼ | -4.777 | 122.210▲ | 150.754▲ |
Friday, June 06, 2025 05:44 AM
Under ABVC's existing licensing framework with OncoX, a share of these revenues will flow back to ABVC in the form of royalty payments, allowing ABVC to capitalize on downstream value. This ...
|
Tuesday, June 03, 2025 03:12 AM
Silicon Valley, CA - (NewMediaWire) - June 03, 2025 - - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing ...
|
Wednesday, May 14, 2025 06:15 AM
SILICON VALLEY, CA - May 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 1.80 | 1.85 | 1.74 | 1.77 | 284,842 |
12/06/25 | 1.67 | 1.85 | 1.58 | 1.85 | 362,574 |
11/06/25 | 1.64 | 1.695 | 1.6008 | 1.67 | 83,406 |
10/06/25 | 1.65 | 1.67 | 1.60 | 1.67 | 228,368 |
09/06/25 | 1.59 | 1.6499 | 1.5493 | 1.62 | 298,634 |
06/06/25 | 1.55 | 1.65 | 1.4801 | 1.54 | 374,542 |
05/06/25 | 1.57 | 1.61 | 1.42 | 1.50 | 349,242 |
04/06/25 | 1.69 | 1.73 | 1.55 | 1.58 | 313,588 |
03/06/25 | 1.62 | 1.81 | 1.62 | 1.65 | 532,312 |
02/06/25 | 1.38 | 1.61 | 1.38 | 1.54 | 591,711 |
|
|
||||
|
|
||||
|
|